ES2255484T3 - Terapia con chaperonina 10 y beta-interferon para la esclesosis multiple. - Google Patents

Terapia con chaperonina 10 y beta-interferon para la esclesosis multiple.

Info

Publication number
ES2255484T3
ES2255484T3 ES00903434T ES00903434T ES2255484T3 ES 2255484 T3 ES2255484 T3 ES 2255484T3 ES 00903434 T ES00903434 T ES 00903434T ES 00903434 T ES00903434 T ES 00903434T ES 2255484 T3 ES2255484 T3 ES 2255484T3
Authority
ES
Spain
Prior art keywords
cpn10
ifn
day
treatment
eae
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00903434T
Other languages
English (en)
Spanish (es)
Inventor
Halle Morton
Alice Cavanagh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
University of Queensland UQ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Queensland UQ filed Critical University of Queensland UQ
Application granted granted Critical
Publication of ES2255484T3 publication Critical patent/ES2255484T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Surgical Instruments (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES00903434T 1999-01-20 2000-01-20 Terapia con chaperonina 10 y beta-interferon para la esclesosis multiple. Expired - Lifetime ES2255484T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP8239/99 1999-01-20
AUPP8239A AUPP823999A0 (en) 1999-01-20 1999-01-20 A treatment

Publications (1)

Publication Number Publication Date
ES2255484T3 true ES2255484T3 (es) 2006-07-01

Family

ID=3812443

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00903434T Expired - Lifetime ES2255484T3 (es) 1999-01-20 2000-01-20 Terapia con chaperonina 10 y beta-interferon para la esclesosis multiple.

Country Status (12)

Country Link
US (1) US20090214473A1 (https=)
EP (1) EP1150703B1 (https=)
JP (1) JP4691257B2 (https=)
KR (1) KR100694011B1 (https=)
AT (1) ATE313332T1 (https=)
AU (2) AUPP823999A0 (https=)
CA (1) CA2361081C (https=)
DE (1) DE60024967T2 (https=)
DK (1) DK1150703T3 (https=)
ES (1) ES2255484T3 (https=)
PT (1) PT1150703E (https=)
WO (1) WO2000043033A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ548985A (en) * 2004-01-16 2010-02-26 Cbio Ltd Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
BG66458B1 (bg) 2005-03-21 2014-10-31 Иван Иванов Средство за конкурентно инхибиране на ендогенен гама интерферон
EP2457930A1 (en) 2005-08-31 2012-05-30 CBIO Limited Modified chaperonin 10
CN101330922A (zh) * 2005-10-20 2008-12-24 悉生物有限公司 超敏的治疗
CA2644058C (en) * 2006-03-02 2016-08-09 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
US9359421B2 (en) 2008-04-08 2016-06-07 Tigo Gmbh Suppressor of the endogenous interferon-gamma
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015339A1 (en) * 1993-11-30 1995-06-08 The University Of Queensland Antagonists to chaperonin 10
JPH10500109A (ja) * 1994-05-10 1998-01-06 イミユロジク・フアーマシユーチカル・コーポレーシヨン 多発性硬化症のための組成物および治療方法
DE19544768C1 (de) * 1995-11-30 1997-07-10 Rentschler Arzneimittel Verwendung einer Kombination aus Pentoxifyllin mit Typ-I-Interferonen zur Behandlung der Multiplen Sklerose

Also Published As

Publication number Publication date
KR20020002376A (ko) 2002-01-09
ATE313332T1 (de) 2006-01-15
AU2527100A (en) 2000-08-07
CA2361081C (en) 2010-09-21
JP4691257B2 (ja) 2011-06-01
EP1150703B1 (en) 2005-12-21
EP1150703A1 (en) 2001-11-07
JP2002535286A (ja) 2002-10-22
KR100694011B1 (ko) 2007-03-12
CA2361081A1 (en) 2000-07-27
DE60024967D1 (en) 2006-01-26
PT1150703E (pt) 2006-05-31
WO2000043033A1 (en) 2000-07-27
DK1150703T3 (da) 2006-05-29
EP1150703A4 (en) 2004-11-10
DE60024967T2 (de) 2006-08-17
US20090214473A1 (en) 2009-08-27
AU771867B2 (en) 2004-04-01
AUPP823999A0 (en) 1999-02-11

Similar Documents

Publication Publication Date Title
Miller et al. The “T” in trauma: the helper T-cell response and the role of immunomodulation in trauma and burn patients
US20090214473A1 (en) Combination chaperonin 10 and beta-interferon therapy for multiple sclerosis
Krosnick et al. Augmentation of antitumor efficacy by the combination of recombinant tumor necrosis factor and chemotherapeutic agents in vivo
JP5989727B2 (ja) 造血におけるｉｌ−１２の使用
EP1401474B1 (en) Methods for inducing sustained immune response
CN1379664A (zh) 利用活性氧代谢物抑制剂活化和保护细胞毒性淋巴细胞
SK91696A3 (en) Use of il-10 to stimulate peripheral blood mononuclear cell cytolytic activity
ES2224124T3 (es) Metodo para tratar enfermedades autoinmunes usando interferones de tipo uno.
CN107582566A (zh) 通过多胺化合物调控自身免疫性疾病的方法和组合物
WO2005018542A2 (en) Use of lactoferrin in prophylaxis against infection and/or inflammation in immunosuppressed subjects
Jung et al. Therapeutic effect of transforming growth factor-beta 2 on actively induced EAN but not adoptive transfer EAN
Thong et al. Immunopotentiation by pyrimethamine in the mouse
US5871725A (en) Use of IL-10 to stimulate peripheral blood mononuclear cell cytolytic activity
Rizzo et al. Interferon alpha-2a and vinblastine in the treatment of metastatic renal carcinoma
US20030206962A1 (en) Method for treating cancer patients undergoing chemotherapy
JPH09510737A (ja) 化学療法剤を増強するためのｉｌ−４の使用
ES2778630T3 (es) Composición multipeptídica
Michelson et al. Polyadenylic· Polyuridylic Acid in the Cotreatment of Cancer
US20050147588A1 (en) Methods for treatment of obesity and for promotion of weight loss
JP2583248B2 (ja) 免疫療法剤
Mansour et al. Effect of methotrexate on the response of rat lymphocytes to phytohaemagglutinin
Dray et al. of Tumor-Bearer Lymphoid Cells¹
Goldstein Washington University School of Medicine, Washington, DC 20037
JP2002537265A (ja) 抗腫瘍Ｔｈ１細胞の製造方法
HUT78097A (hu) IL-10 alkalmazása perifériás vér mononukleáris sejt citolitikus aktivitás stimulálására